keyboard_arrow_down
Why Choose Genetic Screening
Genetic screening, as part of fertility treatment, can improve the chance of success, potentially reduce time in care, and provide patients and their care team with powerful information for supporting a healthy pregnancy and delivery.
What is NexCCS?
RMA uses NexCCS, the most advanced embryo screening platform available for IVF today. Validated over several years and multiple rigorous clinical trials, NexCCS can accurately determine if an embryo possesses the right number of chromosomes (euploidy) or too few or too many (aneuploidy). This is important because published data suggests 50-70% of miscarriages are due to aneuploidy. Selection with NexCCS can substantially reduce these risks.
More Accurate than Ever Before
Greater than 98% accuracy1
Detects Subtle Abnormalities
Ability to detect more subtle abnormalities in embryos, such as mosaicism and segmental abnormalities2
High Delivery Rate
69% delivery rate in a large-scale clinical trial3
Single Embryo Transfer
Greatly increases the effectiveness of Single Embryo Transfer (SET) for a healthier pregnancy
NexCCS with Single Embryo Transfer
In the U.S., approximately half of all babies conceived following IVF were born as part of a twin or triplet pregnancy. These pregnancies typically result from a multiple embryo transfer and are associated with a significantly increased risk of problems for the mother and baby.
Utilizing NexCCS to choose the single best embryo for transfer makes the promise of Single Embryo Transfer (SET) a reality and provides a safer and more effective treatment option for many patients.4
Purpose of Testing
- Allows the embryologist to accurately select the highest quality embryo(s) for transfer
- Selecting high-quality embryos improves implantation rates and reduces miscarriage rates
- Greatly increases the effectiveness of Single Embryo Transfer (SET)
- Reduces the risks associated with becoming pregnant with multiples. These risks include increased risk of premature birth and low birth weight babies, increased risk of C-section and time spent in neonatal intensive care units, as well as health risks to the mother.
What to Expect
To begin aneuploidy screening with NexCCS, a sample is biopsied (safely removed) from an embryo. The method of biopsy used in NexCCS has been determined to be the safest available. Approximately five cells are removed from a specific area of the embryo called the trophectoderm at a specific time in embryonic development.
Unlike other methods of biopsy, a trophectoderm biopsy has no significant impact on the reproductive potential of the embryo and therefore maximizes the benefit of NexCCS. The biopsied cells are then sent to the FEC where they are analyzed. About seven days later, a report is sent to the patient’s IVF team.
Interpreting Results
Once the NexCCS report comes in, the doctor will notify the patient to review the results.
- Werner MD, Franasiak JM, Hong KH, Juneau CR, Tao X, Landis J, Upham KM, Treff NR, Scott RT. A prospective, blinded, non-selection study to determine the predictive value of ploidy results using a novel method of targeted amplification based Next generation sequencing (NGS) for comprehensive chromosome screening (CCS). Fertil Steril 2015; 104 (3): Suppl: e12-13.
- Morin SJ, Tiegs A, Jalas C, Landis J, Zhan Y, Neal S, Franasiak J, Scott RT Jr. Higher resolution aneuploidy screening with targeted NGS may increase the pool of transferrable embryos despite inclusion of segmental and mosaic range diagnostic categories. European Society for Human Reproduction and Embryology Annual Meeting. Barcelona, Spain. July 2018
- Marin D, Sun L, Scott RT Jr., Treff N. Increased implantation rates with targeted next generation sequencing (TNGS) compared to QPCR-based comprehensive chromosome screening. Fertil Steril 2017; 108 (3); Suppl: e271.
- Forman, E.J., Hong, K.H., Ferry, K.M., Tao, X., Treff, N.R., Scott, R.T. Blastocyst euploid selective transfer (BEST): an RCT of comprehensive chromosome screening- single embryo transfer (CCS-SET) vs double embryo transfer (DET)- equivalent pregnancy rates, eliminates twins. Fertil Steril 2012; 98: S49.
